The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...

The EMA has started a review of Leo Pharma’s interleukin-13 ... a category that is currently dominated by Sanofi and Regeneron’s Dupixent. The EU regulator is reviewing tralokinumab for ...

Dupixent pen and syringe are two different devices used to inject the drug. They’re prefilled with the same amount of Dupixent and share other features, but certain factors make the pen easier ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Note: The chronological list does not include December approvals. 1. Dupixent (dupilumab) for chronic obstructive pulmonary disease: The monoclonal antibody, already approved for eczema ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...